Nour Heart, Inc.

Dr. Salwa Elgebaly is a Cardio Pharmacologist who founded Nour Heart, Inc. in Hartford, Connecticut, U.S. and she is the Company’s Chief Executive Officer (CEO). Dr. Elgebaly is a former Associate Professor and Director of Surgical Research at the Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, where she is currently an Adjunct faculty. Dr. Elgebaly received her Ph.D. from the University of North Carolina at Chapel Hill, North Carolina, a Master degree from the University of Wisconsin at Madison, Wisconsin, and a Bachelor in Pharmacy from the University of Alexandria at Alexandria, Egypt.

In recognition of her innovative work, Dr. Salwa A. Elgebaly has recently been elected as a Fellow of the American College of Cardiology (FACC). Dr. Salwa A. Elgebaly is also recognized by the Women In Bio (WIB)-Founders. She was selected as a WIB-Entrepreneur Center: Founders Innovation Showcase Finalist to present Nour Heart’s Therapeutic Products (Nourexal®) to Investors in Women in Bio (WIB)-Entrepreneur Center Founders Innovation Showcase held in the 2022 Bio International Convention, San Diego, California. Only 5 women-owned companies were selected nationally to present in the therapeutic field.

Nour Heart’s mission is to develop and commercialize diagnostic and therapeutic products for the early detection, prevention, and treatment of myocardial ischemia in patients with ischemic heart disease. Dr. Elgebaly’s has unique experiences in academia, pharmaceutical industry, and clinical trials, which includes, drug discovery and development, as well as FDA regulations and commercialization. Dr. Elgebaly is the Inventor of fourteen (14) Patents Issued by the U.S. Patent Office and four additional U.S. and international pending patent applications related to Nourin® and Nourexal®. She is also the lead author or senior author in all her publications in peer-reviewed journals, as well as peer-reviewed abstracts presented at the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC).

Dr. Elgebaly is the first to identify, patent, and register the novel molecular biomarker, to early diagnose myocardial ischemia prior to necrosis in patients suspected of having acute coronary syndrome (ACS), consisting of acute myocardial infarction (AMI) and unstable angina (UA). In contrast with current biomarkers such as troponin, Nourin® miRNAs can rapidly identify myocardial ischemia in and confirm its resolution after coronary angioplasty. Nour Heart’s novel blood-based test will have particular benefits for the rapid diagnosis of heart disease in womenwomen, where heart disease goes undiagnosed in many women since their symptoms are vague compared to men. Dr. Elgebaly’s abstract entitled, “microRNA-137 and miRNA-106b are novel myocardial ischemia/inflammation-dependent biomarkers with high diagnostic sensitivity and specificity for acute coronary syndrome (ACS)” submitted to the American College of Cardiology (ACC), is accepted for oral presentation under “Highlighted Original Research: Ischemic Heart Disease and the Year in Review” at the ACC 2024, Atlanta, Georgia.

Dr. Elgebaly also patented and registered the cardioprotective bioenergetic drug, Cyclocreatine Phosphate (CCrP) (Nourexal®) to protect against ischemic injury and restore cardiac function with clinical applications in heart transplantation, high-risk intervention cardiology, and the development of heart failure after heart attack. Recently, the FDA awarded CCrP the Orphan Drug Designation for the heart transplantation indication and the Company is currently conducting CCrP safety assessment for Phase I/Phase II clinical trial. Dr. Elgebaly has extensive experience in conducting FDA-regulated drug testing in Phase II and Phase III clinical trials and functioned as a Director of Clinical Affairs in a Maryland-based pharmaceutical.

In recognition of her unique work on the novel biomarker Nourin®, Dr. Elgebaly was invited by two Nobel Prize Winners in Medicine, Professor Sir John Vane, London, UK, and Professor R. Levi Montalcini, Rome, Italy, to present her work.